Clinical Data 23andMe study explains variable results with obesity drugs PharmaphorumGene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.Clinical DataMetabolic & GLP-1Read full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: EverSea Medicines to acquire Hasten BiopharmaceuticalsNext: The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
